BioInsights - Evolution in gene therapy for the treatment of hemophilia

Evolution in gene therapy for the treatment of hemophilia

Cell & Gene Therapy Insights 2022; 8(4), 251–319

DOI: 10.18609/cgti.2022.048

Published: 1 April 2022
Interview
Roland W Herzog, PhD

David McCall, Commissioning Editor, Cell & Gene Therapy Insights, talks to Roland Herzog, Riley Children’s Foundation Professor of Immunology, and Director of the Gene and Cell Therapy Program at The Herman B Wells Center for Pediatric Research, Indiana University

Roland W Herzog, PhD, is currently Riley Children’s Foundation Professor of Immunology, and Director of the Gene and Cell Therapy Program at The Herman B Wells Center for Pediatric Research at Indiana University. He received a PhD in Microbiology from Auburn University in 1996, followed by postdoctoral training at the Children’s Hospital of Philadelphia and faculty appointments at the University of Pennsylvania and the University of Florida. Dr. Herzog received multiple awards for his research, including from the American Society of Gene and Cell Therapy and the National Hemophilia Foundation. He currently serves as editor-in-chief of Molecular Therapy. His research team develops AAV-based gene therapies and immune tolerance protocols for hemophilia and defines immune response mechanisms to AAV gene therapy vectors and to therapeutic proteins used in replacement therapy for genetic disease.